$-0.25 EPS Expected for Adaptimmune Therapeutics plc (ADAP); 683 Capital Management Lowered Lendingclub (Put) (LC) Position

March 14, 2018 - By Hugh Holland

Analysts expect Adaptimmune Therapeutics plc (NASDAQ:ADAP) to report $-0.25 EPS on March, 15 before the open.They anticipate $0.03 EPS change or 13.64% from last quarter’s $-0.22 EPS. The stock decreased 3.53% or $0.32 during the last trading session, reaching $8.74. About 338,885 shares traded. Adaptimmune Therapeutics plc (NASDAQ:ADAP) has declined 43.56% since March 14, 2017 and is downtrending. It has underperformed by 60.26% the S&P500.

683 Capital Management Llc decreased Lendingclub Corp (Put) (LC) stake by 35.71% reported in 2017Q3 SEC filing. 683 Capital Management Llc sold 250,000 shares as Lendingclub Corp (Put) (LC)’s stock rose 0.53%. The 683 Capital Management Llc holds 450,000 shares with $2.74M value, down from 700,000 last quarter. Lendingclub Corp (Put) now has $1.59 billion valuation. The stock decreased 4.76% or $0.19 during the last trading session, reaching $3.8. About 5.80 million shares traded. LendingClub Corporation (NYSE:LC) has risen 52.97% since March 14, 2017 and is uptrending. It has outperformed by 36.27% the S&P500.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. The company has market cap of $818.82 million. The Company’s platform enables to identify cancer targets; find and genetically engineer T-cell receptors ; and produce TCR therapeutic candidates for administration to patients. It currently has negative earnings. The company's lead program includes NY-ESO-1 and LAGE-1a cancer antigens, which are in Phase I/II clinical trials for patients with solid tumors, as well as hematological cancer types, including synovial sarcoma, multiple myeloma, non-small cell lung cancer (NSCLC), and ovarian cancer; and pilot trial for myxoid round cell liposarcoma.

Among 5 analysts covering Adaptimmune Therapeutics PLC (NASDAQ:ADAP), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Adaptimmune Therapeutics PLC had 5 analyst reports since February 25, 2016 according to SRatingsIntel. The stock of Adaptimmune Therapeutics plc (NASDAQ:ADAP) has “Buy” rating given on Thursday, February 25 by Citigroup. SunTrust maintained Adaptimmune Therapeutics plc (NASDAQ:ADAP) rating on Saturday, November 11. SunTrust has “Buy” rating and $10.0 target. The firm has “Underperform” rating given on Monday, October 24 by Bank of America. The stock of Adaptimmune Therapeutics plc (NASDAQ:ADAP) earned “Buy” rating by Cowen & Co on Tuesday, June 6.

Among 25 analysts covering LendingClub Corporation (NYSE:LC), 6 have Buy rating, 0 Sell and 19 Hold. Therefore 24% are positive. LendingClub Corporation has $24 highest and $2 lowest target. $7.34’s average target is 93.16% above currents $3.8 stock price. LendingClub Corporation had 68 analyst reports since July 31, 2015 according to SRatingsIntel. As per Wednesday, April 19, the company rating was maintained by Stifel Nicolaus. The firm has “Neutral” rating by Citigroup given on Thursday, February 22. The stock of LendingClub Corporation (NYSE:LC) earned “Hold” rating by Canaccord Genuity on Tuesday, August 8. The rating was upgraded by Sterne Agee CRT to “Buy” on Wednesday, November 18. Goldman Sachs maintained the shares of LC in report on Wednesday, May 18 with “Neutral” rating. Credit Suisse maintained the stock with “Neutral” rating in Tuesday, August 9 report. The firm has “Outperform” rating given on Friday, October 30 by FBR Capital. FBR Capital maintained LendingClub Corporation (NYSE:LC) on Friday, February 12 with “Outperform” rating. Morgan Stanley maintained it with “Overweight” rating and $6.5 target in Wednesday, November 8 report. The stock has “Sell” rating by Compass Point on Friday, February 12.

Investors sentiment decreased to 0.87 in Q3 2017. Its down 0.32, from 1.19 in 2017Q2. It fall, as 26 investors sold LC shares while 42 reduced holdings. 23 funds opened positions while 58 raised stakes. 337.60 million shares or 4.08% more from 324.35 million shares in 2017Q2 were reported. Tiaa Cref Ltd Liability Co stated it has 825,418 shares. Guggenheim Capital Ltd Liability Company reported 85,449 shares or 0% of all its holdings. Barclays Public Limited Company has invested 0% of its portfolio in LendingClub Corporation (NYSE:LC). Canada Pension Plan Investment Board reported 0.01% in LendingClub Corporation (NYSE:LC). Banque Pictet And Cie Sa reported 66,000 shares. Blume Capital Mgmt Inc reported 0% stake. Royal Retail Bank Of Canada owns 33,005 shares. State Board Of Administration Of Florida Retirement System invested in 145,271 shares. Ubs Asset Management Americas Incorporated has invested 0% of its portfolio in LendingClub Corporation (NYSE:LC). 149,713 were reported by Voya Investment Management Lc. Norwest Venture Prns X LP accumulated 12.82M shares or 57.31% of the stock. Amalgamated Bank accumulated 40,502 shares. Tpg Grp Holdg (Sbs) Advsr holds 320,000 shares. Glenmede Trust Na owns 1,500 shares for 0% of their portfolio. Profund Advsrs Lc, Maryland-based fund reported 13,014 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News